Ansbert Gadicke, M.D.
Investment and Operations Team
Dr. Ansbert Gadicke is co-founder and Managing Director of MPM and its venture capital activities, as well as Managing Partner of the UBS Oncology Impact Fund (OIF), an oncology-only private/public fund managed by MPM. He is the driving force at MPM behind building leading biopharmaceutical companies such as BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), and Pharmasset (acquired by Gilead Sciences) and, more recently, Cullinan Oncology (NASDAQ: CGEM), iTeos Therapeutics (NASDAQ: ITOS) and AlloVir (NASDAQ: ALVR). MPM believes that these companies, in which Ansbert was the lead investor and served on the Boards of Directors, are some of the biggest successes in biotech – companies that ultimately result in helping thousands of patients live longer and vastly improved lives. For example, Sovaldi, developed by Pharmasset, was the first cure for Hepatitis C and experienced the most successful product launch in the pharmaceutical industry. Prior to launching MPM’s venture investing activities, Ansbert led MPM’s Advisory and Investment Banking business, and prior to that he was at The Boston Consulting Group in their Boston office.
Ansbert’s commitment to drug discovery and curing disease inspires his work both within and outside of MPM. In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Ansbert and his co-founder Luke Evnin are recipients of the 2017 Global Oncology Visionary Award. Ansbert is active in guiding MPM portfolio companies and serves as Chairman of the Board at NextPoint Therapeutics, Orna, and TCR2 Therapeutics (NASDAQ: TCRR) and as a Board Director at Cullinan Oncology (NASDAQ: CGEM), ElevateBio and Allovir (NASDAQ: ALVR). He is also a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.
Ansbert received an M.D. from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. While at the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.